Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Status:
WITHDRAWN
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborators:
Eastern Hepatobiliary Surgery Hospital Sun Yat-sen University